PTHS
Pelthos Therapeutics Inc
$
22.500
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
22.550
Open
21.010
VWAP
22.16
Vol
3.97K
Mkt Cap
68.45M
Low
21.000
Amount
88.06K
EV/EBITDA(TTM)
--
Total Shares
3.04M
EV
67.50M
EV/OCF(TTM)
--
P/S(TTM)
--
Pelthos Therapeutics Inc., formerly Channel Therapeutics Corporation, is a biopharmaceutical company focused on commercializing therapeutic products for high unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The Company is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.
Show More
0 Analyst Rating
Wall Street analysts forecast PTHS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTHS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 22.500
Low
Averages
High
Current: 22.500
Low
Averages
High
The End
See All Ratings
No Data
Valuation Metrics
The current forward P/E ratio for Pelthos Therapeutics Inc (PTHS.A) is -18.82, compared to its 5-year average forward P/E of -13.00. For a more detailed relative valuation and DCF analysis to assess Pelthos Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-13.00
Current PE
-18.82
Overvalued PE
-5.08
Undervalued PE
-20.93
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
1.68
Current PS
2.50
Overvalued PS
2.81
Undervalued PS
0.54
Financials
Annual
Quarterly
FY2025Q2
YoY :
+83.12%
-3.23M
Operating Profit
FY2025Q2
YoY :
+94.68%
-3.45M
Net Income after Tax
FY2025Q2
YoY :
+1654.07%
-53.85
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PTHS News & Events
Events Timeline
2025-08-18 (ET)
2025-08-18
08:05:24
Pelthos Therapeutics announces Q2 EPS of $5.38, up from $3.07 a year ago
Sign Up For More Events
Sign Up For More Events
People Also Watch
XOM
Exxon Mobil Corp
111.280
USD
+1.88%
TSLA
Tesla Inc
340.010
USD
+6.22%
AAPL
Apple Inc
227.760
USD
+1.27%
NVDA
NVIDIA Corp
177.990
USD
+1.72%
META
Meta Platforms Inc
754.790
USD
+2.12%
AMZN
Amazon.com Inc
228.840
USD
+3.10%
WMT
Walmart Inc
96.830
USD
-1.15%
ORCL
Oracle Corp
236.370
USD
+1.38%
MSFT
Microsoft Corp
507.230
USD
+0.59%
AVGO
Broadcom Inc
294.000
USD
+1.52%
FAQ
What is Pelthos Therapeutics Inc (PTHS) stock price today?
The current price of PTHS is 22.5 USD — it has increased 4.9 % in the last trading day.
What is Pelthos Therapeutics Inc (PTHS)'s business?
What is the price predicton of PTHS Stock?
What is Pelthos Therapeutics Inc (PTHS)'s revenue for the last quarter?
What is Pelthos Therapeutics Inc (PTHS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Pelthos Therapeutics Inc (PTHS)'s fundamentals?
How many employees does Pelthos Therapeutics Inc (PTHS). have?